1-3 of 3
David Lavergne, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Murielle Roussel, MD, Anne-Marie Stoppa, MD, Aurore Perrot, MD, Lionel Karlin, MD, Bertrand Arnulf, MD PhD, Margaret Macro, MD, Antoine Huart, MD, Laurent Frenzel, MD PhD, Pierre Morel, MD, Eileen Boyle, MD, Veronique Dorvaux, MD, Giampaolo Merlini, MD, Giovanni Palladini, MDPhD, David Lavergne, PhD, Frank Bridoux, MD PhD, Arnaud Jaccard
Journal: Blood
Blood (2017) 130 (Supplement 1): 508.
https://doi.org/10.1182/blood.V130.Suppl_1.508.508
Published: 2017
Journal Articles

Incidence and Prevalence of Light Chain Amyloidosis: A Population-Based Study

Suzanne Duhamel, MD, Dania Mohty, MD PhD, Julien Magne, PhD, David Lavergne, PhD, Dominique Bordessoule, MD, Victor Aboyans, MD PhD, Arnaud Jaccard
Journal: Blood
Blood (2017) 130 (Supplement 1): 5577.
https://doi.org/10.1182/blood.V130.Suppl_1.5577.5577
Published: 2017
Journal Articles

Risk and Response Adapted Conventional Treatment Strategy in 146 Patients with AL Amyloidosis

Arnaud Jaccard, MD, Frank Bridoux, MD, Estibaliz Lazaro, MD, Olivier Tournilhac, MD, Margareth Macro, MD, Murielle Roussel, MD, Bruno Moulin, MD, Xavier Leleu, MD, Mamoun Did, MD, Sylvain Choquet, MD, Pierre Morel, MD, Bruno Royer, MD, David Lavergne, PhD, Charlotte Rigaud, MD, Jean Paul Fermand, MD
Journal: Blood
Blood (2014) 124 (21): 2131.
https://doi.org/10.1182/blood.V124.21.2131.2131
Published: 2014